CNS Pharmaceuticals Inc (CNSP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.09M
Last updated: Nov 17, 2026 at 4:10 PM ET
CNS Pharmaceuticals Inc (CNSP) Statistics
CNS Pharmaceuticals (CNSP) has a market cap of $5.09M. Its share count is up 1798.93% from a year earlier. It holds $17.21M more cash than debt, 338.43% of its market cap.
Total Valuation
| Market Cap | $5.09M |
|---|---|
| Latest price (Nov 17, 2026) | $4.15 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 39.86% over 52 weeks and trades 14.96% below its 50-day average.
| Beta (1Y) | 0.05 |
|---|---|
| 52-Week Change | -39.86% |
| 1-Month Change | -16.83% |
| 3-Month Change | -28.82% |
| 6-Month Change | -13.18% |
| 5-Year Change | -100.00% |
| Total Return (1Y) | -39.86% |
| Total Return (3Y CAGR) | -96.27% |
| Total Return (5Y CAGR) | -91.70% |
| Return vs SPY (1Y) | -49.85% |
| Max Drawdown (1Y) | -72.66% |
| Max Drawdown (3Y) | -100.00% |
| Sharpe Ratio (1Y) | -0.32 |
| Correlation with SPY (1Y) | 0.00 |
| 50-Day Average | $4.88 |
| 200-Day Average | $4.45 |
| 52-Week Range | $1.90 to $10.54 |
| RSI (14 Days) | 47.5 |
| Average Volume (20 Days) | 18.68K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.65x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.65x |
|---|---|
| Quick Ratio | 7.65x |
| Debt / Equity | 0.00x |
| Interest Coverage | -1019.01x |
Returns and Efficiency
Return on equity is -101.75% and return on assets is -88.46% over the last 12 months.
| Return on Equity (ROE) | -101.75% |
|---|---|
| Return on Assets (ROA) | -88.46% |
| ROIC (5Y Average) | -78.77% |
Scores
CNSP has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | $2.90K |
| Operating Income | -$16.33M |
| Pretax Income | -$15.98M |
| Net Income | -$15.98M |
| Reported EPS (TTM) | -$18.07 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 86.99% of the $18.06M in total assets.
| Cash and Equivalents | $17.21M |
|---|---|
| Total Debt | $0 |
| Net Cash | $17.21M |
| Net Cash Per Share | $1.62 |
| Working Capital | $15.69M |
| Shareholder Equity | $15.71M |
| Book Value Per Share | $1.48 |
| Total Assets | $18.06M |
| Total Liabilities | $2.36M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$14.01M |
|---|---|
| FCF Per Share | -$9.61 |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
CNSP does not pay a dividend.
| Buyback Yield | -49.29% |
|---|---|
| Shareholder Yield | -49.29% |
Stock Splits
The last split was a 1-for-12 reverse split on Jul 22, 2025.
| Last Split Date | Jul 22, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CNSP
What is CNSP's market cap?
CNS Pharmaceuticals has a market cap of $5.09M.
How many shares of CNSP are outstanding?
CNS Pharmaceuticals has 10.61M shares outstanding. The count is up 1798.93% from a year earlier.
Does CNSP pay a dividend?
No. CNS Pharmaceuticals does not pay a dividend.
How much debt does CNSP have?
CNS Pharmaceuticals has $0 of total debt and $17.21M of cash and equivalents, a net cash position of $17.21M.
CNSP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors